1
|
Liu C, Wei H, Zhang X, Wu W, Shen Z, Luo F, Deng S. Establishment of a reverse genetics system for an epidemic strain of porcine rotavirus JXAY01 type G5P[23]I12. Front Vet Sci 2025; 11:1512327. [PMID: 40012614 PMCID: PMC11862993 DOI: 10.3389/fvets.2024.1512327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2024] [Accepted: 12/19/2024] [Indexed: 02/28/2025] Open
Abstract
Porcine rotavirus is one of the most important pathogens causing diarrhea in newborn piglets, and the genome of this virus contains 11 double-stranded RNA segments, which are easy to be recombined among strains to produce new strains with different antigenic properties. The reverse genetics system is an informative tool for studying virus biology. Recently, adaptable plasmid-based reverse genetics systems were developed for the porcine rotavirus OSU strain; however, such systems have not been developed for epidemic porcine rotavirus genotypes in China. In this study, we successfully established a reverse genetic system based on an epidemic strain of porcine rotavirus JXAY01 isolated in recent years, which was characterized by a specific genotype constellation: G5-P[23]-I12-R1-C1-M1-A8-N1-T7-E1-H1. 11 gene segments of porcine rotavirus JXAY01 were cloned into plasmid vectors similar to the SA11 system. JXAY01 genome segment plasmids were co-transfected with 10 complementary SA11 genome plasmids, and 11 monoreassortant strains were successfully rescued. Viral replication analyses of the parental SA11 strain and the monoreassortant strains showed that the structural protein replacement monoreassortants had reduced cell proliferation compared with the parental SA11 and non-structural protein replacement strains. The recombinant rJXAY01 strain could be successfully rescued using 11 pRG-JXAY01 plasmids. Whole genome sequencing showed 12 amino acid differences between the isolate JXAY01 and the recombinant rJXAY01, but there was no significant difference in their in vitro replication ability. This study reports the reverse genetic system, which lays the foundation for further understanding of porcine rotavirus molecular biology and novel vaccine development.
Collapse
Affiliation(s)
- Changjin Liu
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
- The College of Life Science, Nanchang Normal University, Nanchang, China
| | - Huangsiwu Wei
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
- Lushan Botanical Garden, Jiangxi Province and Chinese Academy of Science, Lushan, China
| | - Xingyi Zhang
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
| | - Wenjie Wu
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
| | - Zhengqiao Shen
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
| | - Feng Luo
- Jiangxi Jinyibo Biotechnology Company, Nanchang, China
| | - Shunzhou Deng
- Department of Preventive Veterinary Medicine, College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
| |
Collapse
|
2
|
Patton JT, Desselberger U. Rotaviruses and Rotavirus Vaccines: Special Issue Editorial. Viruses 2024; 16:1665. [PMID: 39599780 PMCID: PMC11598851 DOI: 10.3390/v16111665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Accepted: 10/16/2024] [Indexed: 11/29/2024] Open
Abstract
Species A rotaviruses (RVA) are a major cause of acute gastroenteritis in infants and young children and in the young of various mammalian and avian species [...].
Collapse
Affiliation(s)
- John T. Patton
- Department of Biology, Indiana University, 212 S Hawthorne Drive, Simon Hall 011, Bloomington, IN 47405, USA
| | - Ulrich Desselberger
- Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK;
| |
Collapse
|
3
|
Kawagishi T, Sánchez-Tacuba L, Feng N, Greenberg HB, Ding S. Reverse Genetics of Murine Rotavirus: A Comparative Analysis of the Wild-Type and Cell-Culture-Adapted Murine Rotavirus VP4 in Replication and Virulence in Neonatal Mice. Viruses 2024; 16:767. [PMID: 38793648 PMCID: PMC11125933 DOI: 10.3390/v16050767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 05/03/2024] [Accepted: 05/05/2024] [Indexed: 05/26/2024] Open
Abstract
Small-animal models and reverse genetics systems are powerful tools for investigating the molecular mechanisms underlying viral replication, virulence, and interaction with the host immune response in vivo. Rotavirus (RV) causes acute gastroenteritis in many young animals and infants worldwide. Murine RV replicates efficiently in the intestines of inoculated suckling pups, causing diarrhea, and spreads efficiently to uninoculated littermates. Because RVs derived from human and other non-mouse animal species do not replicate efficiently in mice, murine RVs are uniquely useful in probing the viral and host determinants of efficient replication and pathogenesis in a species-matched mouse model. Previously, we established an optimized reverse genetics protocol for RV and successfully generated a murine-like RV rD6/2-2g strain that replicates well in both cultured cell lines and in the intestines of inoculated pups. However, rD6/2-2g possesses three out of eleven gene segments derived from simian RV strains, and these three heterologous segments may attenuate viral pathogenicity in vivo. Here, we rescued the first recombinant RV with all 11 gene segments of murine RV origin. Using this virus as a genetic background, we generated a panel of recombinant murine RVs with either N-terminal VP8* or C-terminal VP5* regions chimerized between a cell-culture-adapted murine ETD strain and a non-tissue-culture-adapted murine EW strain and compared the diarrhea rate and fecal RV shedding in pups. The recombinant viruses with VP5* domains derived from the murine EW strain showed slightly more fecal shedding than those with VP5* domains from the ETD strain. The newly characterized full-genome murine RV will be a useful tool for dissecting virus-host interactions and for studying the mechanism of pathogenesis in neonatal mice.
Collapse
Affiliation(s)
- Takahiro Kawagishi
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
- VA Palo Alto Health Care System, Department of Veterans Affairs, Palo Alto, CA 94304, USA
| | - Liliana Sánchez-Tacuba
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
- VA Palo Alto Health Care System, Department of Veterans Affairs, Palo Alto, CA 94304, USA
| | - Ningguo Feng
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
- VA Palo Alto Health Care System, Department of Veterans Affairs, Palo Alto, CA 94304, USA
| | - Harry B. Greenberg
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
- VA Palo Alto Health Care System, Department of Veterans Affairs, Palo Alto, CA 94304, USA
| | - Siyuan Ding
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| |
Collapse
|
4
|
Snyder AJ, Agbemabiese CA, Patton JT. Production of OSU G5P[7] Porcine Rotavirus Expressing a Fluorescent Reporter via Reverse Genetics. Viruses 2024; 16:411. [PMID: 38543776 PMCID: PMC10974435 DOI: 10.3390/v16030411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 03/04/2024] [Accepted: 03/05/2024] [Indexed: 05/23/2024] Open
Abstract
Rotaviruses are a significant cause of severe, potentially life-threatening gastroenteritis in infants and the young of many economically important animals. Although vaccines against porcine rotavirus exist, both live oral and inactivated, their effectiveness in preventing gastroenteritis is less than ideal. Thus, there is a need for the development of new generations of porcine rotavirus vaccines. The Ohio State University (OSU) rotavirus strain represents a Rotavirus A species with a G5P[7] genotype, the genotype most frequently associated with rotavirus disease in piglets. Using complete genome sequences that were determined via Nanopore sequencing, we developed a robust reverse genetics system enabling the recovery of recombinant (r)OSU rotavirus. Although rOSU grew to high titers (~107 plaque-forming units/mL), its growth kinetics were modestly decreased in comparison to the laboratory-adapted OSU virus. The reverse genetics system was used to generate the rOSU rotavirus, which served as an expression vector for a foreign protein. Specifically, by engineering a fused NSP3-2A-UnaG open reading frame into the segment 7 RNA, we produced a genetically stable rOSU virus that expressed the fluorescent UnaG protein as a functional separate product. Together, these findings raise the possibility of producing improved live oral porcine rotavirus vaccines through reverse-genetics-based modification or combination porcine rotavirus vaccines that can express neutralizing antigens for other porcine enteric diseases.
Collapse
Affiliation(s)
- Anthony J. Snyder
- Department of Biology, Indiana University, 212 S. Hawthorne Drive, Simon Hall 011, Bloomington, IN 47405, USA; (A.J.S.); (C.A.A.)
| | - Chantal A. Agbemabiese
- Department of Biology, Indiana University, 212 S. Hawthorne Drive, Simon Hall 011, Bloomington, IN 47405, USA; (A.J.S.); (C.A.A.)
- Department of Electron Microscopy and Histopathology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra 00233, Ghana
| | - John T. Patton
- Department of Biology, Indiana University, 212 S. Hawthorne Drive, Simon Hall 011, Bloomington, IN 47405, USA; (A.J.S.); (C.A.A.)
| |
Collapse
|
5
|
Agbemabiese CA, Philip AA, Patton JT. Recovery of Recombinant Rotaviruses by Reverse Genetics. Methods Mol Biol 2024; 2733:249-263. [PMID: 38064037 DOI: 10.1007/978-1-0716-3533-9_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]
Abstract
Rotaviruses are the primary cause of severe gastroenteritis in infants and young children throughout the world. To combat rotavirus illness, several live oral vaccines have been developed, or are under development, that are formulated from attenuated human or human-animal reassortant strains of rotavirus. While the effectiveness of these vaccines is generally high in developed countries, the same vaccines are significantly less effective in many developing countries, where the need for rotavirus vaccines is greatest. Recently, reverse genetics systems have been developed that allow modification of the segmented double-stranded (ds)RNA genome of rotavirus, including reprogramming the genome to allow expression of additional proteins that may stimulate expanded neutralizing antibody responses in vaccinated children. The use of reverse genetics systems may not only lead to the development of more potent classes of vaccines but can be used to better explore the intricacies of rotavirus molecular biology and pathogenesis. In this article, we share protocols that can be used to generate recombinant rotaviruses, including modified strains that express foreign proteins.
Collapse
Affiliation(s)
- Chantal A Agbemabiese
- Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
- Department of Biology, Indiana University, Bloomington, IN, USA
| | - Asha A Philip
- Department of Biology, Indiana University, Bloomington, IN, USA
- CSL Seqirus, Waltham, MA, USA
| | - John T Patton
- Department of Biology, Indiana University, Bloomington, IN, USA.
| |
Collapse
|
6
|
Philip AA, Hu S, Dai J, Patton JT. Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2. J Gen Virol 2023; 104:001899. [PMID: 37830788 PMCID: PMC10721933 DOI: 10.1099/jgv.0.001899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 09/21/2023] [Indexed: 10/14/2023] Open
Abstract
Reverse genetic systems have been used to introduce heterologous sequences into the rotavirus segmented double-stranded (ds)RNA genome, enabling the generation of recombinant viruses that express foreign proteins and possibly serve as vaccine vectors. Notably, insertion of SARS-CoV-2 sequences into the segment seven (NSP3) RNA of simian SA11 rotavirus was previously shown to result in the production of recombinant viruses that efficiently expressed the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the S1 region of the SARS-CoV-2 spike protein. However, efforts to generate a similar recombinant (r) SA11 virus that efficiently expressed full-length S1 were less successful. In this study, we describe modifications to the S1-coding cassette inserted in the segment seven RNA that allowed recovery of second-generation rSA11 viruses that efficiently expressed the ~120-kDa S1 protein. The ~120-kDa S1 products were shown to be glycosylated, based on treatment with endoglycosidase H, which reduced the protein to a size of ~80 kDa. Co-pulldown assays demonstrated that the ~120-kDa S1 proteins had affinity for the human ACE2 receptor. Although all the second-generation rSA11 viruses expressed glycosylated S1 with affinity for the ACE receptor, only the S1 product of one virus (rSA11/S1f) was appropriately recognized by anti-S1 antibodies, suggesting the rSA11/S1f virus expressed an authentic form of S1. Compared to the other second-generation rSA11 viruses, the design of the rSA11/S1f was unique, encoding an S1 product that did not include an N-terminal FLAG tag. Probably due to the impact of FLAG tags upstream of the S1 signal peptides, the S1 products of the other viruses (rSA11/3fS1 and rSA11/3fS1-His) may have undergone defective glycosylation, impeding antibody binding. In summary, these results indicate that recombinant rotaviruses can serve as expression vectors of foreign glycosylated proteins, raising the possibility of generating rotavirus-based vaccines that can induce protective immune responses against enteric and mucosal viruses with glycosylated capsid components, including SARS-CoV-2.
Collapse
Affiliation(s)
- Asha A. Philip
- Department of Biology, Indiana University, Bloomington, IN 47405, USA
- Present address: CSL Seqirus, 225 Wyman Street, Waltham, MA 02452, USA
| | - Sannoong Hu
- Department of Biology, Indiana University, Bloomington, IN 47405, USA
| | - Jin Dai
- Department of Biology, Indiana University, Bloomington, IN 47405, USA
| | - John T. Patton
- Department of Biology, Indiana University, Bloomington, IN 47405, USA
| |
Collapse
|
7
|
Wei J, Radcliffe S, Pirrone A, Lu M, Li Y, Cassaday J, Newhard W, Heidecker GJ, Rose II WA, He X, Freed D, Citron M, Espeseth A, Wang D. A Novel Rotavirus Reverse Genetics Platform Supports Flexible Insertion of Exogenous Genes and Enables Rapid Development of a High-Throughput Neutralization Assay. Viruses 2023; 15:2034. [PMID: 37896813 PMCID: PMC10611407 DOI: 10.3390/v15102034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/29/2023] Open
Abstract
Despite the success of rotavirus vaccines, rotaviruses remain one of the leading causes of diarrheal diseases, resulting in significant childhood morbidity and mortality, especially in low- and middle-income countries. The reverse genetics system enables the manipulation of the rotavirus genome and opens the possibility of using rotavirus as an expression vector for heterologous proteins, such as vaccine antigens and therapeutic payloads. Here, we demonstrate that three positions in rotavirus genome-the C terminus of NSP1, NSP3 and NSP5-can tolerate the insertion of reporter genes. By using rotavirus expressing GFP, we develop a high-throughput neutralization assay and reveal the pre-existing immunity against rotavirus in humans and other animal species. Our work shows the plasticity of the rotavirus genome and establishes a high-throughput assay for interrogating humoral immune responses, benefiting the design of next-generation rotavirus vaccines and the development of rotavirus-based expression platforms.
Collapse
Affiliation(s)
- Jiajie Wei
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Scott Radcliffe
- Department of Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, USA; (S.R.); (W.A.R.II)
| | - Amanda Pirrone
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Meiqing Lu
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Yuan Li
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Jason Cassaday
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - William Newhard
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Gwendolyn J. Heidecker
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - William A. Rose II
- Department of Quantitative Biosciences, Merck & Co., Inc., West Point, PA 19486, USA; (S.R.); (W.A.R.II)
| | - Xi He
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Daniel Freed
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Michael Citron
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Amy Espeseth
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| | - Dai Wang
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, PA 19486, USA; (A.P.); (M.L.); (Y.L.); (J.C.); (W.N.); (G.J.H.); (X.H.); (D.F.); (M.C.); (A.E.); (D.W.)
| |
Collapse
|